AI Startup Amissa Targets Menopause Care
Amissa, an NIH-backed startup, has launched an AI-powered platform to address what it calls a "$24.8 billion data blind spot" in menopause care. The platform is designed to help clinical providers structure symptom data and close care gaps for an often-underrepresented patient population. The company's launch was also covered here.
- Amissa's B2B platform integrates patient data from sources including the Menopause Rating Scale (MRS) questionnaire and wearables like the Apple Watch, Oura, Garmin, and Whoop, structuring it for clinicians to use within their existing EHR workflow. - The company was founded in 2017 with a focus on using wearable data for Alzheimer's research and received an NIH grant for this work; the founders pivoted to menopause after uncovering research suggesting a strong link between hormonal changes during menopause and the fact that two-thirds of dementia patients are women. - While the global menopause market is projected to reach $600 billion by 2030, startups focused on this area receive only about 7% of total femtech funding. - The platform is designed to operate in a HIPAA-compliant manner by selling directly to clinical practices, which pay a per-clinician fee, distinguishing its data privacy model from direct-to-consumer wellness apps. - Amissa's CEO, Samantha Smith, notes that a key value proposition is organizing symptom data, as many electronic health records (EHRs) lack the specific fields needed to track menopause symptoms longitudinally. - The company's focus on structuring currently under-tracked data aims to address the estimated $24.8 billion in excess annual U.S. healthcare spending linked to unrecognized or unmanaged menopause symptoms. - Competitors in the menopause space include direct-to-consumer virtual providers like Midi Health, Evernow, and Gennev, while Amissa differentiates itself by being a B2B platform focused on empowering existing clinicians with better data.
